Ganagliflozin proline attenuates osteogenic dysfunction and inflammatory signaling during exposure to advanced glycation end products in murine osteoblasts
World Journal of Diabetes · 2026-11-15 · 17 (11)
DOI: 10.4239/wjd.124042 ↗Abstract
BACKGROUND Advanced glycation end products (AGEs) accumulate in diabetes, disrupt the collagen I-rich bone matrix, activate inflammatory signaling involving the receptor for AGEs (RAGE) and nuclear factor kappa B (NF-κB), and impair osteoblast function. Ganagliflozin proline (Gana Pro), a sodium-glucose cotransporter 2 inhibitor, may protect bone, but its effects on AGE-induced osteogenic dysfunction remain unclear. AIM To determine whether Gana Pro attenuates AGE-induced osteogenic dysfunction and examine associated collagen I and inflammatory signaling changes. METHODS AGE accumulation was measured by enzyme-linked immunosorbent assay. Molecular docking assessed potential AGE-collagen I interactions, and collagen I-methylglyoxal co-incubation assessed modification. AGE-treated MC3T3-E1 cells received canagliflozin or Gana Pro. Cell viability, proliferation, cell-cycle distribution, collagen I, inflammatory signaling, osteogenic markers, alkaline phosphatase activity, and mineralization were evaluated using molecular, cellular, imaging, and staining assays. Separate RAGE-knockdown experiments with phorbol 12-myristate 13-acetate (PMA) stimulation assessed pathway involvement. RESULTS Higher AGE levels were observed under 25 mmol/L glucose than under 5.5 mmol/L glucose. Exploratory docking predicted non-covalent poses of representative AGE-related molecules within a fibronectin-collagen peptide complex, while methylglyoxal increased AGE-related fluorescence in a cell-free collagen I system. Commercial AGE-bovine serum albumin (BSA) exposure was associated with reduced MC3T3-E1 viability, proliferation, collagen I, osteogenic markers, alkaline phosphatase activity, and mineralization, together with increased RAGE, p65 phosphorylation, and tumor necrosis factor alpha (TNF-α). Gana Pro, particularly at 5 μM, improved proliferation, collagen I and osteogenic marker expression, alkaline phosphatase activity, calcium deposition, and mineralization, while reducing RAGE, p65 phosphorylation, and TNF-α. Separately, RAGE knockdown reduced AGE-BSA-associated p65 phosphorylation and restored osteogenic markers, whereas PMA partially attenuated this recovery. CONCLUSION Gana Pro attenuated AGE-induced osteogenic dysfunction, accompanied by restored collagen I and reduced RAGE/NF-κB inflammatory signaling; direct pharmacological rescue is required to establish pathway mediation.
EUVIMED